Callaway Golf is investing $15 million in a new advanced 3D printing facility in Fort Worth, Texas, to enhance its manufacturing and R&D capabilities. This facility will enable the creation of complex titanium golf club designs that were previously impossible with conventional methods, aiming to improve performance and accelerate innovation. The plant is expected to be operational by mid-2027 and will initially focus on custom titanium products. This move builds on Callaway's seven years of additive manufacturing research and complements its $100 million investment in golf ball manufacturing in Massachusetts, reinforcing its commitment to advanced U.S. manufacturing and technological leadership in golf equipment.
Callaway Golf's new U.S. investment in advanced 3D printing technology is notable context for readers. For those following the Consumer Cyclical sector, 39 of 134 US stocks rose while 90 fell. Notable movers include Harley-Davidson Inc at USD 34.04 with a 4.48% increase and Life Time Group Holdings Inc. at USD 45.00 down 5.76%. Data is as of Nov 06, 2026 19:31 WIB.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
